Posted inTechnology News
Osimertinib offers a hint of added benefit for NSCLC patients who have received adjuvant chemotherapy
Osimertinib was the first drug to be approved for adjuvant treatment after complete tumour resection in adults with stage IB to IIIA non-small cell lung cancer (NSCLC). from News Medical…